37 min ago | Richmond Times-Dispatch
Intelliject gets financing for product development
Intelliject Inc., a Richmond-based company that developed a device for treatment of severe allergic reactions, said Tuesday it has received a $15 million loan to help it create a pipeline of new products.
Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 5
This is a continuation of my previous article on biotechnology stocks to watch ahead of ASCO 2012.
Sanofi to test cancer-starving compound in China in 2013
Sanofi-Aventis plans to begin testing a novel compound that is designed to starve liver cancer to death in a phase one human clinical trial in China and possibly South Korea in 2013.
Lawmakers approve 'sponsored research' tweak to public records law
Arizona lawmakers are hoping a newly enacted tweak in the state's public records law leads to a new influx of companies willing to pay state universities to do research for them.
FDA approves Plavix as a generic
A scientist for the French firm Sanofi-Aventis, which made and marketed the blood-thinner with Bristol-Myers Squibb.
BUYINS.NET: Market Maker Surveillance Report. LOW, LUK, SNY, ARMH,...
BUYINS.NET: Market Maker Surveillance Report. LOW, LUK, SNY, ARMH, GEN, QQQ, Bearishly Biased Price Friction For Thursday, May 17th 2012 BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday.
3 Dow Movers with News You Must Know
McDonald's Corp. affirms a report in China Daily that says it increased the four different products by 1 yuan , at the end of April, marking the second price bump so far this year.
Societe Generale Now Covering Sanofi-Aventis
Sanofi-Aventis opened at 35.92 on Thursday. Sanofi-Aventis has a 52-week low of $30.98 and a 52-week high of $40.58. The company has a market cap of $95.098 billion and a price-to-earnings ratio of 11.62. SNY has been the subject of a number of other recent research reports.
IPO Preview: Rib-X Pharmaceuticals
Based in New Haven, CT, Rib-X Pharmaceuticals scheduled a $75 million IPO with a market capitalization of $204 million at a price range mid-point of $13 for Wednesday, May 9, 2012.
Sanofi lays off 112 workers as part of 2014 plant closing
Sanofi has begun the phased process of laying off workers at its Kansas City manufacturing plant and expects to completely close the operation by the August of 2016, four years later than originally expected.
Ex-Sanofi worker sentenced to prison for stealing, selling company trade secrets
Sanofi-Aventis' headquarters in Paris. A former worker at the drug maker's U.S. headquarters in Bridgewater was sentenced today to 18 months in prison for stealing company trade secrets.
Just Released: "Sanofi-aventis Pakistan limited (SAPL) - Financial...
The company manufactures its products in the areas of thrombosis, central nervous system disorders, diabetes, vaccines, oncology, cardiovascular diseases, and internal medicine, as well as neurodegenerative diseases, metabolic disorders, allergies and infectious diseases.
Thank you for your interest in the Supv Quality Control. To begin the application process, please enter your email address.
Sanofi-Aventis Given "Neutral" Rating at Zacks
's stock had its "neutral" rating restated by Zacks in a report issued on Tuesday.
Shire's Stumble Could Help Protalix on Gaucher's Treatment
April 29--Trading in shares of Protalix Biotherapeutics Inc. has been heavy in recent weeks, ahead of a decision by US Food and Drug Administration whether to approve the company's treatment for Gaucher's disease Uplyso.